Doctors not informed of harmful effects of medicines during sales visits

A new UBC study compares the amount of information about a medicine's health benefits and harmful effects given to a family physician during a visit from pharmaceutical sales representatives in Canada, the U.S. and France. (Figure: UBC)

The majority of family doctors receive little or no information about harmful effects of medicines when visited by drug company representatives, according to an international study involving Canadian, U.S. and French physicians.

Yet the same doctors indicated that they were likely to start prescribing these drugs, consistent with previous research that shows prescribing behaviour is influenced by pharmaceutical promotion.

The study, which had doctors fill out questionnaires about each promoted medicine following sales visits, was published online today in the Journal of General Internal Medicine. It shows that failed to provide any information about common or serious side effects and the type of patients who should not use the medicine in 59 per cent of the promotions. In Vancouver and Montreal, no potential harms were mentioned for 66 per cent of promoted medicines.

"Laws in all three countries require sales representatives to provide information on harm as well as benefits," says lead author Barbara Mintzes of the University of British Columbia. "But no one is monitoring these visits and there are next to no sanctions for misleading or inaccurate promotion."

Serious risks were mentioned in only six percent of the promotions, even though 57 per cent of the medications involved in these visits came with US "black box" or Health Canada boxed warnings – the strongest drug warning that can be issued by both countries.

"We are very concerned that doctors and patients are left in the dark and patient safety may be compromised," says Mintzes, an expert on in UBC's School of Population and Public Health.

Doctors in Toulouse were more likely to be told of a harmful effect in a promotional visit, compared to doctors in Canada and the U.S., according to the study. Researchers suggested that this may reflect stricter for promotion of medicines in France.

add to favorites email to friend print save as pdf

Related Stories

Docs not immune to drug marketing: study

Oct 19, 2010

Pharmaceutical promotion may cause doctors to prescribe more expensively, less appropriately and more often, according to a new study co-authored by York University professor Joel Lexchin.

FDA urges docs to report misleading drug ads

May 11, 2010

(AP) -- The Food and Drug Administration said Tuesday it will begin asking doctors to keep an eye out for misleading drug advertisements as part of the agency's latest effort to police the pharmaceutical industry's multibillion-dollar ...

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

4 hours ago

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

8 hours ago

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.